Table 4.
Variable | No. patients (%) | Interval | Univariate analysis | Multivariable analysis | ||
---|---|---|---|---|---|---|
HR | 95% CI | HR | 95% CI | |||
Age | 288 (100) | 1-year increment | 1.02 | 1.00 to 1.04 | 1.02 | 0.99 to 1.06 |
Male | 147 (51) | Versus female | 0.97 | 0.53 to 1.63 | – | – |
Ulceration (n=143) | 14(10) | Versus no ulceration | 1.46 | 0.30 to 6.21 | 0.53 | 0.06 to 4.46 |
Plica involved (n=287) | 31(11) | Versus no involvement | 0.84 | 0.59 to 1.20 | 0.33 | 0.03 to 3.13 |
Caruncle involved (n=288) | 32(11) | Versus no involvement | 0.81 | 0.57 to 1.16 | 1.18 | 0.15 to 9.25 |
Tumour stage (cT2) | 34 | Versus T1 | 0.99 | 0.41 to 2.38 | 2.92 | 0.66 to 12.84 |
Tumour Stage (cT3) | 15 | Versus T1 | 3.06* | 1.07 to 8.70 | 8.06** | 1.55 to 41.67 |
Tumour stage (Tx) | 21 | Versus T1 | 1.89 | 0.57 to 6.19 | 2.15 | 0.70 to 7.21 |
Invasive melanoma (n=288) | 219(76) | Versus no invasion | 1.01 | 0.68 to 1.49 | 0.82 | 0.59 to 1.14 |
Tumour thickness (n=201) | 201 (70) | 1 mm increment | 0.99 | 0.83 to 1.17 | 0.82 | 0.59 to 1.14 |
*p=0.04.
**p=0.013.
†n=number of reports available.
CI, confidence interval; HR, hazard ratio. em dash, not calculable.